Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015 by Jepsen, Martin T. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Incidence and seasonality of respiratory syncytial virus hospitalisations in young
children in Denmark, 2010 to 2015
Jepsen, Martin T.; Trebbien, Ramona; Emborg, Hanne Dorthe; Krause, Tyra G.; Schønning,
Kristian; Voldstedlund, Marianne; Nielsen, Jens; Fischer, Thea Kølsen
Published in:
Eurosurveillance
DOI:
10.2807/1560-7917.ES.2018.23.3.17-00163
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jepsen, M. T., Trebbien, R., Emborg, H. D., Krause, T. G., Schønning, K., Voldstedlund, M., ... Fischer, T. K.
(2018). Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark,
2010 to 2015. Eurosurveillance, 23(3), [17-00163]. https://doi.org/10.2807/1560-7917.ES.2018.23.3.17-00163
Download date: 03. Feb. 2020
1www.eurosurveillance.org
Surveillance and outbreak report
Incidence and seasonality of respiratory syncytial virus 
hospitalisations in young children in Denmark, 2010 to 
2015
Martin T. Jepsen1,2, Ramona Trebbien1,2, Hanne-Dorthe Emborg¹, Tyra G. Krause¹, Kristian Schønning3,4, Marianne Voldstedlund¹, 
Jens Nielsen¹, Thea K. Fischer1,5
1. Statens Serum Institut, Copenhagen S, Denmark
2. These authors contributed equally to this manuscript.
3. Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre, Denmark
4. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
5. Department of Infectious Diseases and Centre of Global Health, University of Southern Denmark, Odense, Denmark
Correspondence: Thea Kølsen Fischer (thf@ssi.dk)
Citation style for this article: 
Jepsen Martin T., Trebbien Ramona, Emborg Hanne Dorthe, Krause Tyra G., Schønning Kristian, Voldstedlund Marianne, Nielsen Jens, Fischer Thea K.. Incidence 
and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill. 2018;23(3):pii=17-00163. https://doi.
org/10.2807/1560-7917.ES.2018.23.3.17-00163 
Article submitted on 04 Mar 2017 / accepted on 25 Jun 2017 / published on 18 Jan 2018
For future decisions on respiratory syncytial virus 
(RSV)-vaccination strategies and implementation into 
national immunisation-programmes, we used national 
registry data (hospitalisation, microbiology and vital 
statistics) to determine the age-specific incidence 
and direct medical costs of annual RSV-associated 
admissions in children < 5 years-old for the period of 
2010–2015. We identified ca 2,500 RSV-associated hos-
pitalisations annually amounting to total direct medi-
cal-costs of ca EUR 4.1 million per year. The incidence 
of RSV-associated hospitalisations peaked in infants 
1–2 months of age followed by infants 2–3 months of 
age, and infants < 1 month of age, respectively. Infant 
boys were at higher risk of severe RSV infection as 
compared to infant girls: male-to-female ratio peaked 
with 1.4 at four months of age and gradually levelled 
out with increasing age to 1.0 at 4 years of age. Five 
RSV-associated deaths were identified. Our findings 
demonstrate that in a western country as Denmark, 
RSV constitutes a considerable burden on childhood 
health. Furthermore, the best approach to reduce the 
high incidence of RSV-associated hospitalisations in 
young infants < 3 months of age may be maternal vac-
cination due to general challenges in achieving suf-
ficient and protective immune responses in young 
infants.
Introduction 
Respiratory syncytial virus (RSV) is the most common 
cause of hospitalisation among children admitted for 
obstructive airway disease throughout the world [1,2]. 
Although RSV infections occur frequently in all age 
groups the youngest infants have the highest rates of 
RSV respiratory disease [3-7]. Globally, an estimated 
3.4 million children younger than 5  years of age are 
hospitalised each year with severe RSV lower respira-
tory tract infection (LRTI), with the highest incidence 
in children younger than 6  months of age [1]. Studies 
have demonstrated a peak incidence of LRTI occur-
ring between 2 and 4  months of age [8,9]. RSV infec-
tion typically manifests clinically with cough, fever 
and nasal congestion in combination with a charac-
teristic wheezing [10] which is caused by inflammation 
(bronchiolitis) and blockage of the narrow airways. 
Young age, prematurity, heart and lung diseases and/
or immunosuppression are risk-factors for severe out-
comes of RSV infection [11]. Natural RSV infection does 
not confer long lasting immunity against subsequent 
infection, and consequently, RSV infections may reoc-
cur throughout a lifetime [11-13].
RSV is the only agent of the three most common organ-
isms that cause death from respiratory-tract infec-
tions in infants (RSV,  Streptococcus pneumoniae, 
and  Haemophilus influenzae),  for which no vaccine 
is currently available [14]. Prophylactic treatment 
with RSV-specific neutralising antibodies often is the 
only preventive as well as therapeutic option left for 
high-risk infants in privileged resource settings [15]. 
Prevention of severe RSV disease through active immu-
nisation of infants and/or during pregnancy would be 
optimal, but this has in previous immunisation attempts 
been extremely challenging [16]. Currently, multiple 
RSV vaccine candidates are undergoing development 
for human use, and some vaccines for infant use are 
in phase 3 of clinical testing [17,18]. The vaccine types 
include recombinant live-attenuated vaccines as well 
as a variety of inactivated candidates, either for vac-
cinating the infant shortly after birth or vaccinating the 
mother during pregnancy to boost maternal antibodies 
2 www.eurosurveillance.org
and thus confer protection of the child [19]. In prepara-
tion for licensure of vaccines, it is pertinent to update 
disease burden estimates to ensure a solid evidence-
based platform for decisionmaking with regards to 
implementation of future RSV vaccines.
In 2015, the World Health Organization (WHO) has 
made it a high priority to establish globally compat-
ible RSV disease burden surveillance systems and 
robust age-specific estimates are particularly in focus 
in order to target optimal age for immunisation [20]. A 
considerable fraction of RSV disease burden studies 
are based on data collected at sub-regional or single-
hospital level or data collected as a part of vaccine tri-
als [7,21,22]. Larger national as well as international 
disease burden studies are often based on estimates 
of the RSV burden from acute LRTIs’ surveillance and 
laboratory results [23].
In this population-based study, we took advantage of 
the unique national registries available in Denmark. 
We linked information on hospital admitted individuals 
registered with an RSV diagnosis in the national patient 
registry (NPR) with information on RSV testing using 
a national microbiology test database (MiBa) [24]. 
We estimated age-specific RSV hospitalisation rates 
in children below 5  years of age in the period from 1 
January 2010 to 26 June 2015. In addition, we described 
seasonality and trends over time, the average length 
of hospital stay and the direct healthcare-related costs 
associated with severe RSV disease.
Methods 
Study design and setting
We performed a retrospective population-based study 
of all children younger than 5 years of age and born in 
or immigrated to Denmark in the period from 1 January 
2010 to 26 June 2015 to determine age- and sex-specific 
rates and trends of RSV-associated hospitalisations. 
Data on national RSV-associated hospitalisations were 
linked to data on RSV test results obtained from the 
MiBa [24].
Denmark has a temperate climate, occupies an area of 
42,895 km2, and has a population of 5,647,923 as of 
January 2016. The yearly birth-cohort in Denmark is ca 
60,000 individuals and the number of children below 
5 years of age in the study period 1 January 2010 to 26 
June 2015 was 315,883. Healthcare is free of charge 
in Denmark, and no private alternative is available for 
hospitalisation of children with respiratory illness. All 
microbiology laboratories testing human samples are 
public and an electronic copy of all test reports are 
transferred to MiBa. Over the study period, there was 
no major change in RSV testing practices and the prev-
alence of RSV-positive tests remained relatively con-
stant during this time (data not shown).
Registries
The Danish Civil Registration System (CRS) was estab-
lished on 1 April 1968 and since then a unique personal 
identification number has been assigned to all Danish 
residents. CRS contains continuously updated informa-
tion on vital status. Census data were retrieved from 
Statistics Denmark, StatBank Denmark from 1 January 
2010 to 30 June 2015.
MiBa includes all microbiological test results from the 
11 departments of clinical microbiology in Denmark 
since 1 January 2010. The records include information 
on unique personal identification number, sample 
date, laboratory analysis, test result and which labora-
tory performed the analysis [24].
The Danish NPR contains information on all hospitalisa-
tions in Denmark since January 1977, including outpa-
tient treatments since 1995. Individual information on 
Figure 1
Monthly respiratory syncytial virus-hospitalisation incidence per 1,000 children up to 12 months of age, in Denmark, 
during the study period, 1 January 2010–26 June 2015
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dates of admission and discharge, and diagnoses are 
registered for every hospitalisation. Since 1994 diagno-
ses are classified according to the World Health ICD-10 
(International Statistical Classification of Diseases and 
Health-related Problems, 10th Revision) [25]. To identify 
acute LRTI-associated hospitalisations including RSV-
associated hospitalisations, we extracted the ICD-10 
diagnoses as listed in Table 1.
The Danish Register of Causes of Death [26] was used 
to identify RSV-coded deaths and data were available 
from the period of 1 January 2010 to 31 December 2014. 
There were no records for 2015.
RSV case definition
A RSV case was defined as a child younger than 
60 months of age (i.e. < 5 years-old), who had been reg-
istered as an inpatient in the NPR, that is, hospitalised, 
with an RSV-specific diagnosis or admitted to hospital 
with another respiratory diagnosis, but with a labora-
tory-confirmed positive RSV test result within a period 
of +/− 7 days spanning the hospital admission. If sev-
eral RSV-associated hospitalisations were recorded 
for an individual, only episodes > 30 days apart were 
included as a separate RSV hospitalisation. This inter-
val was considered adequate in length to distinguish 
episodes of RSV-associated hospitalisations, as only 
few cases would be expected to have more than one 
episode of RSV-associated hospitalisation. Thus, visits 
to the emergency departments have not been included 
in the study if they have not resulted in hospitalisation. 
Paediatric intensive care unit (ICU) data were also not 
taken into account.
RSV-associated mortality
Two methods were employed to identify RSV-associated 
deaths. Any death caused by RSV and registered in the 
Register of Causes of Death was the direct method. 
The other indirect method captured deaths in individu-
als who had died either during hospitalisation or within 
30 days after hospital discharge with an RSV-specific 
diagnosis and/or positive RSV test result linking vital 
status in the CRS and hospitalisation in the NPR. 
Deaths were reviewed on a case basis including infor-
mation (ICD-10 codes) on comorbidity and considered 
RSV-associated, unless another likely cause of death 
was included in the most recent ICD-10 codes associ-
ated to the deceased before death.
RSV seasons
RSV seasons were analysed on an annual basis using a 
calendar year starting in week 33 during the last warm 
summer month of August with median temperatures of 
17 °C and ending in week 32 the following year, which 
was in the middle of the period when fewest RSV cases 
were observed. For the first season 2010, only RSV 
cases admitted to the hospital from 1 January 2010 to 
week 32 in 2010 were available.
Figure 2
Duration in days of respiratory syncytial virus-associated hospitalisations among children < 5 years of age by age groups, in 
Denmark, during the study period, 1 January 2010–26 June 2015
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Direct healthcare expenses associated with 
RSV-hospitalisations
The length of hospitalisation was calculated from 
admission date to discharge date from the NPR. The 
algorithm used to define courses of admissions has 
previously been described [27].
The expenses related to the public healthcare system 
are centrally regulated and according to the Danish 
Health Data Authority, the price per hospitalisation for 
RSV-associated disease < 6 days is EUR 2,000 (Danish 
kroner (DKK) 14,892 at a May 2016 exchange rate of 
DKK 744 to EUR 100) [28]. If the hospitalisation is 6 
days or longer, the cost is EUR 262 (DKK 1,951) per 24 
hours of added stay. These costs are total costs and 
based on average expenditures for mild as well as 
severe RSV-associated hospitalisations in Denmark. 
The costs include all hospitalisation-associated expen-
ditures (e.g. hospital bed, diagnostic work up, health-
care personnel, rehydration treatment and intensive 
care) and cannot be segregated further into various 
expenditure categories.
Statistical analyses
The numbers of children younger than 5 years who were 
hospitalised for RSV-associated disease in Denmark 
were calculated according to age groups: incidence 
rates were estimated per 1,000 in the following age 
groups; < 1 month, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 months, 
0–11  months, 12–23  months, 24–35  months, 
36–47  months and 48–59  months. Patients with a 
positive laboratory test, but without a registered hos-
pitalisation, were excluded as these cases were not 
considered severe. Pvalue for RSV incidence was cal-
culated using the chi-squared test. All descriptive and 
statistical analyses were carried out in Stata version 
12.1.
Results 
Number of severe RSV cases and age 
distribution
During the study period of 1 January 2010 to 26 June 
2015, 10,843 hospitalisations had an ICD-10 code com-
patible with RSV infection. When linking the NPR infor-
mation on hospital admission (Table 1) periods to the 
RSV test-positive results in MiBa by the unique per-
sonal identification number an additional 1,487 (12.1%) 
unique episodes of RSV-associated hospitalisations 
were identified in children with other respiratory diag-
noses. In total, 12,330 RSV-associated hospitalisations 
were identified in the cohort of children <  5  years of 
age during the study period representing 346,444 per-
son-years. The average incidence of severe RSV cases 
expressed as annual RSV-associated hospitalisation 
rate was 7.1 per 1,000 children <  5  years of age with 
9,539 (77%) of the hospitalisations occurring among 
children <  12  months of age, and 7,409 (60%) in chil-
dren <  6  months of age. The average annual hospitali-
sation rates were 45.9 per 1,000 children < 6 months of 
age and 29.4 per 1,000 children <  12  months of age, 
respectively, with the highest rate of 75.7 per 1,000 
infants 1–2 months of age (Table 2). The monthly RSV-
hospitalisation incidence per 1,000 children during 
the 5 year study period also consistently identified the 
infants 1  month of age as having the highest rate of 
hospitalisation (Figure 1). 
On average, 2,466 Danish children < 5 years of age were 
hospitalised due to severe RSV infection annually, 
ranging from the lowest 1,456 in the 2013/14 season to 
the highest 2,834 in the 2012/13 season.
The median age for RSV hospitalisation was 7.7 months 
(interquartile range (IQR): 1.9–11.1 months).
Table 1
ICD-10 code used for identification of respiratory syncytial virus (RSV) associated hospitalisations for the entire study 
period, Denmark, 1 January 2010–26 June 2015 (n = 12,330 hospitalisations)
Diagnostic category ICD-10 code Number Percentage
RSV specifieda
RSV as the cause of diseases classified to other chapters B97.4 916 7.4
RSV pneumonia J12.1 3,844 31.2
Acute bronchitis and acute bronchitis with bronchospasm J20.5 3,517 28.5
Acute bronchiolitis J21.0 2,566 20.8
Total RSV specifieda NA 10,843 87.1
RSV ‘other’a b 1,487 12.9
Total NA 12,330 100
MiBa: Danish National Microbiology Database; NA: not applicable.
a The ICD-10 codes are divided in (i) RSV specified and (ii) other respiratory diagnoses (RSV ‘other’), where a positive RSV diagnostic test 
result was identified in MiBa, respectively.
b Influenza: J09.X, J10.X, J11.X; pneumonia, non-influenza viruses: J12.X, J16.X, J17.X, J18.X; pneumonia, virus unspecified; J18.9; bronchitis 
and bronchiolitis: J20.X, J21.X, J40.X, J42.X; not further specified lower respiratory infection: J22.X. X indicates all diagnoses starting with 
this code.
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Seasonality
RSV-associated hospitalisations demonstrated a dis-
tinct seasonal variation with peaks in the winter months 
of December through March and almost no cases dur-
ing the summer months of June through September.
Every other year the RSV season had an early start in 
weeks 46 to 48 (Figure 1), and was rather mild in terms 
of hospitalisations (2009/10, 2011/12, and 2013/14). 
Every alternating year the RSV-season would start a 
few weeks later (week 50–52) and be characterised 
with a markedly higher RSV-hospitalisation incidence 
(2010/11, 2012/13, and 2014/15).
Sex distribution
Of the 12,330 hospitalisations, 6,901 (55.9%) occurred 
among young boys resulting in an overall male to female 
ratio of 1.3. The sex ratio (male to female) was high-
est in the first months of life, peaked among infants 
4  months of age (1.4) (n = 882) and gradually levelled 
out with increasing age to 1.0 in children 4 years of age 
(n = 63).
Mortality
During the study period, one child was recorded in the 
Register of Causes of Death registry as having died of 
RSV-associated infection. Additionally, by use of the 
indirect method, 28 children of the total of 12,330 RSV 
cases were registered as no longer alive in the CRS. 
When linking the date of death to the RSV-associated 
hospitalisation admission and discharge dates, four of 
the 28 children were identified as having died either 
during hospitalisation or within 30  days of being dis-
charged from hospital with a RSV-specific diagnosis 
and/or RSV positive test result. Of the deaths identi-
fied by use of the indirect method two children died 
in the hospital whereby the discharge date and date 
of deaths are identical, one child died within 24 hours 
after being discharged and one child died 3 days after 
being discharged, respectively. In total, five deaths 
among 12,330 RSV cases < 5  years of age resulted in 
a case fatality rate of 0.04%. The median age of the 
RSV-associated deaths was 6.5 months (IQR: 1.0–9.8 
months). Four of the five patients had underlying 
conditions (muscular dystrophy and myopathy, bron-
chopulmonary dysplasia, Steno Fallot’s tetralogy, and 
multiple congenital malformations), and two of these 
were born preterm < week 28, which might have predis-
posed them for severe outcome of RSV disease.
Hospitalisation length of stay
The median length of stay in hospital for the entire 
cohort was 1.96 days (IQR: 0.67–4.17). It was higher 
among children younger than 3 months of age (median 
length-of-stay: 2.71  days; IQR: 0.92–5.21) compared 
with children 3 months or older (median length-of-stay: 
1.62 days; IQR: 0.46–3.71), (p < 0.001) (Figure 2). 
Direct healthcare expenses
Of the 12,330 RSV associated admissions 90.2% 
lasted < 6 days (n = 11,123), and 9.8% (n = 1,207) 
lasted ≥ 6 days (range: 6–103 days) (Figure 2). The total 
direct medical costs of RSV-associated hospitalisations 
therefore amounted to ca EUR 4.1 million (ca DKK 30.5 
million) per year.
Discussion 
A vaccine’s effectiveness to prevent severe disease, 
hospitalisations and deaths is of paramount impor-
tance when weighing pros and cons for introduction of 
new vaccines into national immunisation programmes. 
Due to under-registration, misclassification and lack of 
national guidelines for RSV-testing, hospital diagnosis 
statistics are rarely sufficient to estimate incidence or 
prevalence of RSV-associated disease. In the present 
Table 2
Annual incidence rates of respiratory syncytial virus associated hospitalisations per 1,000 persons by age group, in 
Denmark, in the study period, 1 January 2010–26 June 2015
Age in months Cases Person-years
Incidence rate 
 
(cases per time-at-risk)
95% confidence intervals
< 1 1,215 26,890 45.2 42.7–47.8
1 2,037 26,907 75.7 72.5–79.1
2 1,574 26,903 58.5 55.7–61.5
3 1,088 26,915 40.4 38.1–42.9
4 882 26,950 32.7 30.6–35.0
5 613 26,959 22.7 21.0–24.6
6-11 2,130 163,205 13.1 12.5–13.6
All 0–11 9,539 324,729 29.4 28.8–30.0
12–23 2,138 340,623 6.3 6.0–6.5
24–35 470 349,317 1.3 1.2–1.5
36–47 120 356,851 0.3 0.3–0.4
48–59 63 360,702 0.2 0.1–0.2
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study, we have investigated the burden of severe RSV-
associated disease in children below 5  years of age 
in Denmark using a combination of population-based 
national registries. We demonstrate how combining 
nationwide hospitalisation data and microbiological 
test results, increases the estimates of RSV hospitali-
sations compared with estimates based on the national 
hospital discharge registry alone.
The incidence of severe RSV infections was highest 
among infants and young toddlers and peaked in the 
1 to 2  month-old infants. This is in line with a study 
by Hall et al. 2013 [22], where the highest age-specific 
rate was observed in 1  month-old infants. This age 
specific distribution may reflect rapidly declining lev-
els of protecting maternal antibodies after birth. This 
hypothesis is consistent with findings in a recent study 
from Turkey where anti-RSV IgG positivity in offspring 
dropped from 83% at birth to 73% at 1  month and 
6% at 3  months of age [29]. As the incidence of RSV-
hospitalisations was high already at 1  month of age, 
the vaccination strategy could be either vaccination of 
the infant shortly after birth or maternal vaccination 
before birth. Vaccination of the newborn is challenging 
due to the immaturity of the neonates’ immune system 
and the passively received maternal antibodies, which 
further can impair the response. Maternal vaccination 
before birth, boosting the titre of maternal antibodies 
[30], might provide a more effective protection of the 
neonates as compared with vaccination of a newborn.
Considering a universal RSV immunisation programme 
with an expected moderate to high vaccine-effective-
ness against hospitalisation and deaths, a consider-
able fraction of RSV-associated hospitalisations likely 
could be avoided per year in Denmark. Whether a 
future RSV vaccine would be cost-saving is too early 
to predict as weighing the health benefits of vaccina-
tion against its costs requires a measure like quality-
adjusted life years, which takes both reduced illness 
and death into account, and subsequent cost-effec-
tiveness analyses in which the healthcare-associated 
as well as the societal costs are considered [31]. In this 
study, the cost estimates due to RSV were only based 
on hospitalisation-associated expenses and did not 
take into account indirect costs from socio-economic 
loss, or from absenteeism of parents of infants older 
than 6 months (as the granted Danish maternity leave 
is minimum 6 months).
The observed seasonal variations in RSV hospitali-
sations with the highest incidence during the winter 
months from December through March were in line 
with findings in northern Europe [32-34] and in temper-
ate climate zones of the United States [35,36]. The data 
suggested that fewer hospitalisations occurred in years 
with an early start of the RSV season as compared with 
years with a later start of RSV seasonal activity. The 
2-year cyclic pattern observed in Denmark for RSV 
seasons is in line with other country reports from e.g. 
Finland and Switzerland [32,33,37-40].
In the RSV-affected children under 5 years, the median 
length of hospitalisation was 1.9  days, and not sur-
prisingly longer (2.7 days) in infants < 3 months of age. 
Other studies have reported similar age-associated 
differences in length of stays among RSV-hospitalised 
infants of 2 days [41], 3 days [42-44], 4 days [45,46],  and 
6  days [47]. Hon et al [48] differentiate length of stay 
further with 8.5  days for paediatric ICU patients and 
3  days for children not in the ICU [48]. As many stud-
ies only provide the mean length of stay, despite the 
observations rarely being normally distributed, this 
challenges our ability to identify and compare our find-
ings to that of relevant compatible study settings.
We examined deaths in the Register of Causes of Death 
and deaths occurring during or within 30 days of an 
RSV-associated hospitalisation as possibly due to RSV. 
The majority of the children had underlying illness dur-
ing their last hospitalisation which likely increased their 
risk of a fatal outcome. Therefore the numbers may be 
overestimated. On the other hand, some children may 
have died of RSV without being hospitalised or in the 
aftermath of an RSV hospitalisation due to complica-
tions of the infection. In the present study, a total of 
five of 12,330 cases died within 30 days of hospital 
admission. Compared with a case definition based on 
RSV specific ICD-10 codes alone, which yielded one 
fatal case, combining RSV-associated ICD-10 code with 
a laboratory-confirmed RSV-test result captured four 
more children. Four of the five children had known 
comorbidities. The low mortality rate of 0.04% due to 
RSV infection in our study is in accordance with find-
ings in other western countries e. g. in Spain, where a 
15-year study found a case fatality rate of 0.14% in the 
same age group [49,50].
Limitations and strengths: Data on comorbidity were 
only included for analyses of deceased children and 
not on all cases included. Also, although the NPR con-
tains ICU data, these were not taken into consideration 
in this work. A major strength of the study however, is 
access to national hospitalisation data and a real-time 
national microbiology database where linkage between 
registries using unique personal identifier enables vali-
dation of the use of national patient discharge regis-
tries in assessment of burden of severe RSV-disease. 
Further, the uniformity of data collected in the micro-
biology database including test negative results 
ensures a strong platform for national disease burden 
estimates. Our validation of the national patient dis-
charge registry using national RSV laboratory test data 
demonstrates, not surprisingly, that analyses of RSV-
hospitalisation burden based on ICD-10 codes alone 
result in underestimation of the true burden.
In conclusion, our study provides population based 
estimates on the incidence and costs of RSV-associated 
hospitalisations in children under 5  years of age in a 
western country. An effective RSV vaccine could reduce 
costs and burden related to RSV hospitalisations con-
siderably. We document how severe RSV infection 
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predominantly affects the youngest children and, dem-
onstrate that the most vulnerable age group includes 
the infants 1 to 2 months of age. Knowledge of the age-
specific RSV burden in infants is crucial for future deci-
sions on vaccination strategies including the choice of 
using maternal and/or infant vaccination.
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